This site use cookies
This site uses cookies that help us to improve our site by providing analytics and usage information. By clicking accept or continuing to use this site you are agreeing to our cookie policy. If you do not agree, please close this notice. Learn more

Transforming the lives of those suffering from vision loss

Our mission is to profoundly improve the treatment of patients with retinal vascular diseases and to transform the lives of those suffering from vision loss.

A revolutionary eye drop entering Phase I clinical trials

By exploiting the alternative splicing of vascular endothelial growth factor (VEGF) we aim to use our cutting-edge technology to introduce an eye drop to treat wet AMD and DMO. Our technology has the potential to become the patients’ treatment of choice.

At Exonate, we want to profoundly improve the lives of those suffering from vision loss. We believe that we have the potential to deliver eye drops to treat diseases such as wet AMD and DMO which will not only offer improved quality of life for patients, but also at a much lower administrative cost.

Exonate is funded by international leading investors